NAV

Canertinib

Identification

Generic Name
Canertinib
DrugBank Accession Number
DB05424
Background

Canertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo. Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET.

Type
Small Molecule
Groups
Investigational
Structure
 3D
Similar Structures
Weight
Average: 485.938
Monoisotopic: 485.162995603
Chemical Formula
C24H25ClFN5O3
Synonyms
  • Canertinib
External IDs
  • PD-183805

Pharmacology

Indication

Investigated for use/treatment in breast cancer and lung cancer.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

CI-1033 effectively inhibits the growth of esophageal squamous cell carcinoma which co-expresses both EGFR and HER2 with the inhibition of phosphorylation of both MAPK and AKT. Some studies suggest that CI-1033 holds significant clinical potential in esophageal cancer.

Target Actions Organism
U表皮生长前沿空中管制官tor receptor Not Available Humans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction
Integrate drug-drug
interactions in your software
Abaloparatide The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Canertinib.
Acetaminophen The serum concentration of Acetaminophen can be increased when it is combined with Canertinib.
Articaine The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Articaine.
Benzocaine The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Benzocaine.
Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Benzyl alcohol.
Bupivacaine The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Bupivacaine.
Butacaine The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Butacaine.
Butamben The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Butamben.
Capsaicin The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Capsaicin.
Carbimazole The therapeutic efficacy of Carbimazole can be decreased when used in combination with Canertinib.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
Ingredient UNII CAS InChI Key
Canertinib dihydrochloride ICJ93X8X90 289499-45-2 JZZFDCXSFTVOJY-UHFFFAOYSA-N

Categories

Drug Categories
Chemical TaxonomyProvided byClassyfire
Description
这种化合物属于类的有机排版ounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazanaphthalenes
Sub Class
Benzodiazines
Direct Parent
Quinazolinamines
Alternative Parents
Aniline and substituted anilines/N-arylamides/Alkyl aryl ethers/Aminopyrimidines and derivatives/Chlorobenzenes/Fluorobenzenes/Aryl chlorides/Aryl fluorides/Imidolactams/Morpholines
show 15 more
Substituents
Acrylic acid or derivatives/Alkyl aryl ether/Amine/Amino acid or derivatives/Aminopyrimidine/Aniline or substituted anilines/Aromatic heteropolycyclic compound/Aryl chloride/Aryl fluoride/Aryl halide
show 33 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organofluorine compound, monochlorobenzenes, quinazolines, morpholines (CHEBI:61399)
Affected organisms
Not Available

Chemical Identifiers

UNII
C78W1K5ASF
CAS number
267243-28-7
InChI Key
OMZCMEYTWSXEPZ-UHFFFAOYSA-N
InChI
InChI=1S/C24H25ClFN5O3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29)
IUPAC Name
N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide
SMILES
FC1=C(Cl)C=C(NC2=NC=NC3=CC(OCCCN4CCOCC4)=C(NC(=O)C=C)C=C23)C=C1

References

属l References
  1. Simon GR, Garrett CR, Olson SC, Langevin M, Eiseman IA, Mahany JJ, Williams CC, Lush R, Daud A, Munster P, Chiappori A, Fishman M, Bepler G, Lenehan PF, Sullivan DM: Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study. Clin Cancer Res. 2006 Aug 1;12(15):4645-51. [Article]
  2. Sequist LV: Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Oncologist. 2007 Mar;12(3):325-30. [Article]
PubChem Compound
156414
PubChem Substance
175427000
ChemSpider
137741
BindingDB
4779
ChEBI
61399
ChEMBL
CHEMBL31965
ZINC
ZINC000027439698
Wikipedia
Canertinib

Clinical Trials

Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
2 Completed Treatment Neoplasms, Breast 1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Property Value Source
Water Solubility 0.0155 mg/mL ALOGPS
logP 4.09 ALOGPS
logP 3.9 Chemaxon
logS -4.5 ALOGPS
pKa (Strongest Acidic) 12.54 Chemaxon
pKa (Strongest Basic) 6.87 Chemaxon
Physiological Charge 0 Chemaxon
Hydrogen Acceptor Count 7 Chemaxon
Hydrogen Donor Count 2 Chemaxon
Polar Surface Area 88.61 Å2 Chemaxon
Rotatable Bond Count 9 Chemaxon
Refractivity 130.55 m3·mol-1 Chemaxon
Polarizability 50.36 Å3 Chemaxon
Number of Rings 4 Chemaxon
Bioavailability 1 Chemaxon
Rule of Five Yes Chemaxon
Ghose Filter No Chemaxon
Veber's Rule No Chemaxon
MDDR-like Rule Yes Chemaxon
Predicted ADMET Features
Property Value Probability
Human Intestinal Absorption + 0.9917
Blood Brain Barrier + 0.9577
Caco-2 permeable - 0.5685
P-glycoprotein substrate Substrate 0.6999
P-glycoprotein inhibitor I Inhibitor 0.9152
P-glycoprotein inhibitor II Inhibitor 0.9592
Renal organic cation transporter Inhibitor 0.5
CYP450 2C9 substrate Non-substrate 0.8114
CYP450 2D6 substrate Non-substrate 0.7455
CYP450 3A4 substrate Substrate 0.6732
CYP450 1A2 substrate Non-inhibitor 0.5366
CYP450 2C9 inhibitor Inhibitor 0.5958
CYP450 2D6 inhibitor Non-inhibitor 0.8724
CYP450 2C19 inhibitor Inhibitor 0.5504
CYP450 3A4 inhibitor Inhibitor 0.827
CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.8911
Ames test Non AMES toxic 0.5465
Carcinogenicity Non-carcinogens 0.8916
Biodegradation Not ready biodegradable 1.0
Rat acute toxicity 2.7549 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.5387
hERG inhibition (predictor II) Inhibitor 0.8273
ADMET data is predicted usingadmetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Spectrum Spectrum Type Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets tounlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details 1.表皮生长前沿空中管制官tor receptor
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
属l Function
Ubiquitin protein ligase binding
Specific Function
Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TG...
Gene Name
EGFR
Uniprot ID
P00533
Uniprot Name
表皮生长前沿空中管制官tor receptor
分子量
134276.185 Da

Drug created at November 18, 2007 18:24 / Updated at February 21, 2021 18:51